Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 421 to 435 of 684 results for kidney or kidneys or renal

  1. Nivolumab for adjuvant treatment of invasive urothelial cancer at high risk of recurrence (TA817)

    Evidence-based recommendations on nivolumab (Opdivo) for adjuvant treatment of invasive urothelial cancer at high risk of recurrence.

  2. Intrauterine laser ablation of placental vessels for the treatment of twin-to-twin transfusion syndrome (HTG126)

    Evidence-based recommendations on intrauterine laser ablation of placental vessels for treating twin-to-twin transfusion syndrome. This involves using a laser to seal off some of the blood vessels in the placenta so both babies receive a more equal amount of blood.

  3. Bladder management strategies:- What are the long-term risks and effects on quality of life of different bladder management strategies for lower urinary tract dysfunction in people with neurological disease?

    about which methods are most likely to produce long-term complications (renal impairment, urinary stones and infections, hydronephrosis,...

  4. MiniMed 640G system with SmartGuard for managing blood glucose levels in people with type 1 diabetes (MIB51)

    NICE has developed a medtech innovation briefing (MIB) on MiniMed 640G system with SmartGuard for managing blood glucose levels in people with type 1 diabetes

  5. VA ECMO for extracorporeal cardiopulmonary resuscitation (ECPR) in adults with refractory cardiac arrest (HTG765)

    Evidence-based recommendations on VA ECMO for extracorporeal cardiopulmonary resuscitation (ECPR) in adults with refractory cardiac arrest. This involves using an artificial lung to oxygenate the blood outside the body.

  6. Depression in adults: treatment and management (NG222)

    This guideline covers identifying, treating and managing depression in people aged 18 and over. It recommends treatments for first episodes of depression and further-line treatments, and provides advice on preventing relapse, and managing chronic depression, psychotic depression and depression with a coexisting diagnosis of personality disorder.

  7. Non-alcoholic fatty liver disease (NAFLD): assessment and management (NG49)

    This guideline covers how to identify the adults, young people and children with non-alcoholic fatty liver disease (NAFLD) who have advanced liver fibrosis and are most at risk of further complications. It outlines the lifestyle changes and pharmacological treatments that can manage NAFLD and advanced liver fibrosis.

  8. Delirium: prevention, diagnosis and management in hospital and long-term care (CG103)

    This guideline covers diagnosing and treating delirium in people aged 18 and over in hospital and in long-term residential care or a nursing home. It also covers identifying people at risk of developing delirium in these settings and preventing onset. It aims to improve diagnosis of delirium and reduce hospital stays and complications.

  9. Tacrolimus and pimecrolimus for atopic eczema (TA82)

    Evidence-based recommendations on tacrolimus (Protopic) and pimecrolimus (Elidel) for people with atopic eczema.

  10. Further research into the comparative efficacy and safety of different surgical and ablative treatments would be useful.

    guidance details Comes from guidance Laparoscopic cryotherapy for renal cancer Number IPG405 Date issued August 2011 Other

  11. Cardiac assessment:- What is the clinical and cost effectiveness of cardiac assessment before transplantation?

    and impact. Source guidance details Comes from guidance Renal replacement therapy and conservative management Number NG107

  12. Alpha blockers and ureteroscopy- What is the clinical and cost effectiveness of tamsulosin as an adjunct to ureteroscopy?

    and impact. Source guidance details Comes from guidance Renal and ureteric stones: assessment and management Number NG118

  13. Timing of pre-emptive transplant:- What is the most clinical and cost-effective strategy for timing of pre-emptive transplantation?

    and impact. Source guidance details Comes from guidance Renal replacement therapy and conservative management Number NG107

  14. Frequency of review:- What is the most clinical and cost-effective frequency of review for people on peritoneal dialysis, haemodiafiltration, haemodialysis or conservative management?

    and impact. Source guidance details Comes from guidance Renal replacement therapy and conservative management Number NG107

  15. Metabolic assessment:- What is the clinical and cost effectiveness of full metabolic assessment compared with standard advice alone, in people with recurrent calcium oxalate stones?

    and impact. Source guidance details Comes from guidance Renal and ureteric stones: assessment and management Number NG118